Thrombospondin-1 and its role in the biology of hematological malignancies;Trombospondyna-1 i jej znaczenie w biologii nowotworów układu krwiotwórczego

Acta Haematologica Polonica

Volumn 35, Issue 1, 2004, Pages 15-26

  Wierzbowska, Agnieszka ^a   Krawczyńska, Anna ^a   Wrzesień Kuś, Agata ^a   Sobczak Pluta, Agnieszka ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute leukemia; Angiogenesis; Chronic lymphocytic leukemia; Neoplasia; Thrombospondin 1

Indexed keywords

GELATINASE B; MESSENGER RNA; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

ACUTE LEUKEMIA; ANGIOGENESIS; CELL GROWTH; CHRONIC LYMPHATIC LEUKEMIA; GENE MUTATION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 2942513009     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Lawer J. The functions of thrombospondin-1 and -2. Current Opin in Cell Biol 2000; 12: 634-640.
2. Baenziger NJ, Brodie GN, Majerus PW. A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci USA 1971; 68: 240-249.
3. Lawer JW, Slayter HS, Coligan JE. Isolation and characterisation of a high molecular weight glycoprotein from human blood platelets. J Biol Chem 1978; 269: 3762-3772.
4. Lawer J, Hynes RO. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium binding sites and homologies with several different proteins. J Cell Biol 1986; 103: 1635-1648.
5. Bornstein P, Sage EH. Thrombospondins. Methods in enzymology. Red Rouslahti E, Engvall E; 1994; Academic Press, San Diego CA Vol 245: 62-85.
6. Adams JC. Thrombospondin-1. Int J Biochem Cell Biol 1997; 29: 861-865.
7. Bornstein P. Thrombospondins: structure and regulation of expression. FASEB J 1992; 6: 3290-3299.
8. Dameron KM, Volpert OV, Tainsky MA i wsp.: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. 1994 Science; 265: 1582-1584.
9. Grant SW, Kyshtoobayeva AS, Kurosaki T i wsp.: Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 1998; 22: 185-94.
10. Grossfeld GD, Ginsberg DA, Stein JP i wsp.: Trombospondin-1 expression in bladder cancer: Association with p53 alterations, tumour angiogenesis and tumor progression. J Natl Cancer Institute 1997; 39: 219-227.
11. Tokunga T, Nakamura M, Oshika Y i wsp.: Alterations in tumour supppressor gene pn 53 correlate with inhibition of thrombospondin-1 gene expressio in colon cancer cells. Virchows Arch 1998; 433: 415-418.
12. Mettouchi A, Cabon F, Monteau N i wsp.: SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J 1994; 13: 5668-5678.
13. Beckmann G, Hanke J, Bork P i wsp.: Merging extracellular domains: fold prediction for laminin G-like and amino-terminal thrombospondin-like modules based on homology to pentraxins. J Mol Biol 1998; 275: 725-730.
14. Chen H, Aeschlimann D, Nowlen J i wsp.: Expression and initial characterization of recombinant mouse thrombospondin-1 and thrombospondin-3 FEBS Lett 1996; 337: 36-41.
15. Chandrasekararan S, Guo NH, Rodrigues RG i wsp.: Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha(3)beta(1) integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem 1999; 274: 11408-11416.
16. Adams J, Trucker RP. The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev Dyn 2000; 218: 280-299.
17. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59-69.
18. Ribeiro SMF, Poczatek M, Schultz-Cherry S i wsp: The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-β. J Biol Chem 1999; 274: 13586-13593.
19. Chen H, Herndon ME, Lawer J: The cell biology of thrombospondin-1. 2000 Matrix Biology; 19: 597-614.
20. Gao AG, Lindberg FP, Finn MB i wsp.: Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996; 271: 21-24.
21. Lawer J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell mol Med 2002; 6: 1-12.
22. Lawer J, Sunday M, Thibert Vi wsp.: Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998; 101: 982-992.
23. Crawford SE; Stellmach V, Murphy-Ullrich JE i wsp.: Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998; 93: 1159-1170.
24. Good DJ, Polverini PJ, Rastinejad F i wsp.: A tumor supressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-6628.
25. Streit M, Velasco P, Brown LF i wsp.: Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous sqamous cell carcinoma. Am J Pathol 1999; 155: 441-452.
26. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K i wsp.: Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential and angiogenesis. Cancer Res 1994; 54: 6504-6511.
27. Dawson W, Pearce SFA, Zhong R i wsp.: CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-717.
28. Jimenez B, Volpert OV, Crawford SE i wsp.: Signals leading to apoptosis-dependent inhibition of neovascularisation by thrombospondin-1. Nature Medicine 2000; 6: 41-48.
29. Guo NH, Drutzch HC, Inman JK i wsp.: Thrombospondin-1 and type 1 repeat peptides of thrombospondin 1 specyfically induce apoptosis of endothelial cells. Cancer Res 1997; 57: 1735-1742.
30. Brooks PC, Montgomery AM, Rosenfeld M i wsp.: Integrin alphav beta3 agonists promote tumor regression by inducing apoptosis by angiogenic blood vessels. Cell 1994; 7: 1157-1164.
31. Nor JE, Mitra RS Sutorik MM i wsp.: Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000; 37: 209-218.
32. Rodriguez-Manzaneque JC, Lane TF, Ortega MA i wsp.: Thrombospondin-1 supress tumor growth by a novel mechanism that includes blocade of matrix metalloproteinase-9 activation. Proc Natl Acad Sci USA. 2001; 98: 12485-12490.
33. Iruela-Arispe ML, Lombardo M, Krutzsch HC i wsp.: Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999; 1000: 1423-1431.
34. Nicosia RF i Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994; 124: 183-193.
35. BenEzra D, Griffin BW, Maftzir G i wsp.: Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysacharyde. Invest Ophtalmol Vis Sci 1993, 31: 3601-3608.
36. Bleuel K, Popp S, Fusenig NE i wsp.: Tumor supression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vasculature. Proc Natl Acad Sci USA 1999; 96: 2065-2070.
37. Yao L, Zhao YL, Itoh S i wsp.: Thrombospondin-1 expression in oral squamous cell carcinomas: correlation with tumor vascularity, clinicopathological features and survival. Oral Oncol 2000; 36: 539-544.
38. Clezardin P, Frappart L, Clerget M i wsp.: Expression of thrombospondin (TSP-1) and its receptors (CD36 and CD31) in normal, hyperplastic and neoplastic human breast. Cancer Res 1993; 53: 1421-1430.
39. Zabrenetzky V, Harris CC, Steeg PS I wsp.: Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma. Int J Cancer 1994; 59: 191-195.
40. Miao W, Seng WL, Duquette M i wsp.: Thrombospondine-1 type 1 recombinant proteins inhibit tumor growth. Blood 2001; 97: 1689-1696.
41. Roberts DD: Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J; 1996; 10: 1183-1191.
42. Yabkowitz RVM, Dixit N, Guo DD i wsp.: Activated T cell adhesion to thrombospondin is mediated by the β1 (VLA-4) and β1 (VLA-5) integrins. J Immunol 1993; 151: 149-158.
43. Wilson KE, Li Z, Kara M i wsp: β1 Integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides. J Imunol 1999; 163: 3621-3628.
44. Cantrell D i wsp.: T cell antigen receptor signal transduction pathways. Annu Rev Immunol 1996; 14: 259-274.
45. Fiedler W, Graeven U, Ergun S i wsp.: Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870-1875.
46. Touhami M, Fauvel-Lafeve F, Da Silva N I wsp.: Induction of thrombospondin-1 by all-trans retinoic acid modulates growth and differentiation of HL-60 myeloid leukemia cells. Leukemia 1997; 11: 2137-2142.
47. Li K, Yang M, Yuen PM I wsp.: Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and caspase-3. Int J Mol Med 2003, 12: 995-1001.
48. Liu P, Wang Y, li YH I wsp.: Adenovirus mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leukemia Res 2003; 27: 701-708.
49. Kay NE, Bone ND, Tschumper RC i wsp.: B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molekules. Leukemia 2002; 16: 911-919.
50. Mateo V, Lagneaux L, Bron D i wsp.: CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat Med. 1999; 5: 1277-1284.